PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Abatacept

Drugs in development · updated 30 October 2026

Abatacept: clinical trials and development status

Other names and codes: Orencia

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 21 May 2007

As of 30 October 2026 Abatacept is in 24 active clinical trials (recruiting or ongoing, phases I–III) for 43 diseases. The most advanced phase is III.

24Active trials
IIIMost advanced phase
43Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Abatacept and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 43 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Rheumatoid arthritisIII4NCT03414502
Acute myeloid leukemiaII–III3NCT07366801
Arthritis, JuvenileIII2NCT06654882
Giant cell arteritisIII2NCT04474847
Precursor lymphoblastic lymphoma/leukemiaII–III2NCT07366801
VasculitisIII2NCT04474847
ArteritisIII1NCT04474847
Autoimmune diseaseIII1NCT04474847
Immune System DiseasesIII1NCT04474847
MyocarditisIII1NCT05335928
NeoplasmIII1NCT05335928
Graft-versus-host diseaseII6NCT04380740
Sickle-cell diseaseII4NCT07616154
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII2NCT06859424
ThalassemiaII2NCT03924401
Ankylosing spondylitisII1NCT07138898
Aplastic anemiaII1NCT03924401
Atypical chronic myeloid leukemiaII1NCT07238712
B-cell leukemiaII1NCT06859424
Beta thalassemiaI–II1NCT07599176
Chronic myelomonocytic leukemiaII1NCT06859424
Common variable immunodeficiencyII1NCT04925375
DermatomyositisII1NCT07138898
Fanconi anemiaII1NCT03924401
Granulomatosis with polyangiitisII1NCT07138898
Interstitial lung diseaseII1NCT04925375
LymphomaII1NCT06859424
Myelodysplastic SyndromesII1NCT07238712
MyelofibrosisII1NCT06859424
Myeloproliferative disordersII1NCT06859424

Everything on Abatacept

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch